Key result
CRABP2 knockdown in myofibroblasts preserves LV function and attenuates interstitial fibrosis in mice.
Why the study?
DNA damage and defective repair promote fibroblast activation, but the upstream regulators linking DNA damage responses to profibrotic remodeling remain unclear.
Does CRABP2 modulation affect cardiac fibroblast activation and fibrosis in models of ischemic heart failure?
Does CRABP2 modulation affect cardiac fibroblast activation and fibrosis in models of ischemic heart failure?
CRABP2 drives profibrotic cardiac fibroblast activation by inhibiting MRE11/MRN-mediated DNA repair, identifying the CRABP2-MRE11-MRN axis as a potential therapeutic target for limiting fibrotic remodeling in ischemic heart failure.
Answers are grounded in this paper and cite their sources.
CRABP2 modulation of fibroblasts may influence ischemic remodeling; leaves open therapeutic targeting pending human validation.
Background Cardiac fibrosis is a hallmark of ischemic heart failure and is driven by activated myofibroblasts. DNA damage and defective repair promote fibroblast activation, yet the upstream regulators that couple DNA damage responses to profibrotic remodeling remain unclear. Methods Single‐cell RNA sequencing data sets from human ischemic cardiomyopathy were analyzed to identify fibroblast‐enriched candidate genes. In vivo, Postn promoter‐driven adeno‐associated viruses were used to knock down or overexpress CRABP2 (cellular retinoic acid‐binding protein 2) in an isoproterenol‐induced mouse model, followed by assessment of ventricular function and fibrosis. In vitro, neonatal cardiac fibroblasts were subjected to CRABP2 gain or loss of function and TGF‐β (transforming growth factor‐β) stimulation. Mechanistic studies combined RNA sequencing, immunoprecipitation–mass spectrometry, structural modeling, γ‐H2AX staining, comet assays, and MRE11/MRE11‐RAD50‐NBS1 (MRN) perturbation. Results Single‐cell analyses identify CRABP2 as a fibroblast‐enriched gene upregulated in profibrotic fibroblast subsets in human ischemic hearts. In vivo, CRABP2 knockdown in Postn + myofibroblasts preserves left ventricular function and attenuates interstitial fibrosis, whereas CRABP2 overexpression exacerbates dysfunction and fibrosis in isoproterenol‐treated mice. In vitro, CRABP2 promotes TGF‐β–induced fibroblast migration, proliferation, activation, and collagen production. Mechanistically, CRABP2 binds MRE11, suppresses MRN‐ATM‐CHK2 signaling, and enhances DNA damage accumulation. Inhibiting or silencing MRE11 abrogates the antifibrotic and cardioprotective effects of CRABP2 . Conclusions CRABP2 drives profibrotic cardiac fibroblast activation by inhibiting MRE11/MRN‐mediated DNA repair. The CRABP2‐MRE11‐MRN axis represents a potential therapeutic target for limiting fibrotic remodeling in ischemic heart failure.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied Ischemic heart failure and cardiac fibrosis. CRABP2 knockdown or overexpression was evaluated on Ventricular function and fibrosis. CRABP2 knockdown in myofibroblasts preserved left ventricular function and attenuated interstitial fibrosis, whereas its overexpression exacerbated dysfunction and fibrosis in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: